Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Next Previous
Trial Profile

A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; CAR-T cell therapies (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 19 Dec 2024 Planned End Date changed from 2 Dec 2024 to 2 Sep 2025.
  • 19 Dec 2024 Planned primary completion date changed from 2 Dec 2024 to 2 Sep 2025.
  • 23 Oct 2024 Planned End Date changed from 2 Sep 2024 to 2 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top